Financial Contrast: Zomedica (OTCMKTS:ZOMDF) versus Innovus Pharmaceuticals (OTCMKTS:INNVD)

Volatility and Risk

Zomedica has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Innovus Pharmaceuticals has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500.

Profitability

This table compares Zomedica and Innovus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zomedica	-65.92%	-19.20%	-17.54%
Innovus Pharmaceuticals	-34.51%	-682.54%	-78.57%

Insider & Institutional Ownership

9.0% of Zomedica shares are owned by institutional investors. Comparatively, 10.4% of Innovus Pharmaceuticals shares are owned by institutional investors. 5.6% of Zomedica shares are owned by company insiders. Comparatively, 16.4% of Innovus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Zomedica and Innovus Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zomedica	$32.03 million	3.19	-$81.86 million	($0.02)	-5.22
Innovus Pharmaceuticals	$23.99 million	0.00	-$8.28 million	($4.16)	N/A

Innovus Pharmaceuticals has lower revenue, but higher earnings than Zomedica. Zomedica is trading at a lower price-to-earnings ratio than Innovus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Innovus Pharmaceuticals beats Zomedica on 6 of the 10 factors compared between the two stocks.

About Zomedica

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.